Avalo Therapeutics (NASDAQ:AVTX - Get Free Report)'s stock had its "outperform" rating reaffirmed by equities research analysts at Wedbush in a research report issued on Thursday,RTT News reports. They presently have a $18.00 target price on the stock. Wedbush's price objective suggests a potential upside of 142.26% from the stock's current price. Wedbush also issued estimates for Avalo Therapeutics' Q1 2025 earnings at $0.63 EPS.
Several other brokerages have also commented on AVTX. Piper Sandler started coverage on shares of Avalo Therapeutics in a research report on Friday, February 28th. They set an "overweight" rating and a $48.00 target price on the stock. BTIG Research initiated coverage on shares of Avalo Therapeutics in a report on Thursday, December 19th. They set a "buy" rating and a $40.00 price objective on the stock. One analyst has rated the stock with a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $35.33.
Get Our Latest Stock Analysis on AVTX
Avalo Therapeutics Stock Down 3.0 %
Shares of AVTX traded down $0.23 during mid-day trading on Thursday, hitting $7.43. The company's stock had a trading volume of 7,371 shares, compared to its average volume of 210,327. Avalo Therapeutics has a 1-year low of $4.60 and a 1-year high of $34.46. The firm has a 50-day simple moving average of $7.45 and a 200 day simple moving average of $9.13.
Institutional Investors Weigh In On Avalo Therapeutics
Institutional investors and hedge funds have recently made changes to their positions in the business. Tower Research Capital LLC TRC raised its position in Avalo Therapeutics by 998.4% during the fourth quarter. Tower Research Capital LLC TRC now owns 4,130 shares of the company's stock worth $31,000 after acquiring an additional 3,754 shares during the last quarter. Marshall Wace LLP purchased a new position in shares of Avalo Therapeutics during the 4th quarter worth approximately $114,000. Walleye Capital LLC purchased a new stake in Avalo Therapeutics in the 4th quarter valued at approximately $145,000. Northern Trust Corp purchased a new stake in Avalo Therapeutics in the 4th quarter valued at approximately $168,000. Finally, Bank of Montreal Can purchased a new position in Avalo Therapeutics during the fourth quarter worth $446,000. 87.06% of the stock is currently owned by hedge funds and other institutional investors.
Avalo Therapeutics Company Profile
(
Get Free Report)
Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.
Read More
Before you consider Avalo Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Avalo Therapeutics wasn't on the list.
While Avalo Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market volatility creates opportunity. Our analysts have pinpointed 10 stocks perfectly positioned for exceptional growth this spring, even amid economic uncertainty. Don't miss your chance to access this timely research and invest with confidence.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
